Johnson and Johnson combines Biosense with Cordis subsidiary:
This article was originally published in Clinica
Johnson & Johnson is to merge its Cordis Webster company with Biosense, an acquisition from last October. According to J&J, the move means the company, now to be known as Biosense Webster, will "better serve the needs of cardiologists" and apply its medical sensor technology. Cordis Webster was acquired in 1996 as part of the Cordis deal. The new company's worldwide president will be James Dennis, formerly president of St Jude's cardiac rhythm management division.
You may also be interested in...
Global Medtech Guidance Tracker: May 2023
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Forty-seven documents have been posted on the tracker since its last update.
BMS & Pfizer Win Funding ‘Firsts’ In England For Migraine & Heart Disease Drugs
Bristol Myers Squibb and Pfizer both asked the health technology assessment body NICE to evaluate their respective drugs, Camzyos and Vydura, for use in indications that are narrower than those for which they are – or will potentially be – approved.
European Parliament Wants EU-Wide Pull Incentive Scheme For New Antimicrobials
The three major EU institutions are all calling for urgent action to tackle antimicrobial resistance, with the emphasis very much on incentives for the development of novel medicines and a reduction in overall consumption of antibiotics.